In this study, a mass spectrometry (MS)-based kinetic method (KM) is shown to be successful at analyzing a multichiral center drug stereoisomer, entecavir (ETV), both qualitatively and quantitatively. On the basis of the KM, the bivalent complex ion [MII (A)(ref*)2 ]2+ (MII = divalent metal ion, A = analyte, and ref* = chiral reference) was set as precursor ion in MS/MS. The experiment results suggest strong chiral selectivity between ETV and its isomers when using ZnII coordinated with the chiral reference R-besivance (R-B). The logarithm of the fragment ion abundance ratio and the enantiomeric percentage (%) exhibits a strong linear relation because of the competitive loss of the reference and analyte. The product ion pair [ZnII (R-B)A-H]+ (m/z 733) and [ZnII (R-B)2 -H]+ (m/z 849), together with [R-B + H]+ (m/z 394) and [A + H]+ (m/z 278), can realize the identification of ETV and all of its chiral isomers. Theoretical calculation were also performed using the B3LYP functional with the 6-31G* and LanL2DZ basis set to clarify the mechanism of structural difference of these bivalent complex ions. The results reveal that MS-KM can be used to detect optical impurities without a chiral chromatographic column and fussy sample pretreatment. The established method has been used to determine stereoisomeric impurities of less than 0.1% in ETV crude drug, a demonstration of its simple and effective nature for rapid detection of stereoisomeric impurities.
Keyphrases
- capillary electrophoresis
- mass spectrometry
- liquid chromatography
- acute lymphoblastic leukemia
- ms ms
- high resolution
- high performance liquid chromatography
- ionic liquid
- gas chromatography
- multiple sclerosis
- high resolution mass spectrometry
- single cell
- emergency department
- quantum dots
- liquid chromatography tandem mass spectrometry
- adverse drug
- dna methylation
- high speed
- electronic health record